BiomX (NYSEMKT:PHGE) Shares Down 2.5%

BiomX Inc. (NYSEMKT:PHGEGet Free Report)’s stock price fell 2.5% during mid-day trading on Tuesday . The company traded as low as $0.30 and last traded at $0.30. 37,265 shares traded hands during trading, a decline of 27% from the average session volume of 50,840 shares. The stock had previously closed at $0.31.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of BiomX in a report on Wednesday, August 9th.

Check Out Our Latest Report on BiomX

BiomX Stock Down 2.5 %

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The company has a market capitalization of $13.89 million, a PE ratio of -0.40 and a beta of 1.34. The company has a 50-day moving average of $0.34 and a two-hundred day moving average of $0.35.

Hedge Funds Weigh In On BiomX

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in shares of BiomX by 149.7% during the 2nd quarter. Renaissance Technologies LLC now owns 195,495 shares of the company’s stock valued at $70,000 after acquiring an additional 117,195 shares during the last quarter. Susquehanna International Group LLP increased its stake in BiomX by 372.4% during the first quarter. Susquehanna International Group LLP now owns 195,598 shares of the company’s stock worth $60,000 after acquiring an additional 154,189 shares during the last quarter. Millennium Management LLC raised its position in BiomX by 208.6% during the fourth quarter. Millennium Management LLC now owns 270,848 shares of the company’s stock valued at $51,000 after purchasing an additional 183,091 shares during the period. Finally, Jane Street Group LLC purchased a new stake in BiomX during the first quarter valued at approximately $48,000. 36.67% of the stock is currently owned by hedge funds and other institutional investors.

BiomX Company Profile

(Get Free Report)

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).

Featured Stories

Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with's FREE daily email newsletter.